^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review
Published date:
06/11/2021
Excerpt:
Molecular analysis of BCR/ABL mutation on ABL kinase showed that BCR/ABL T315I mutation....The patient achieved complete remission after 2 courses’ treatment, followed by one course of clarithromycin regimen and another two courses of VDPI regimen. Patient remains in complete remission...
Secondary therapy:
prednisone + daunorubicin + vinorelbine
DOI:
10.1097/MD.0000000000026323
